Re: Jurczok N, Dernbach G, Ebner B, et al. Multiregional immune profiling reveals prognostic patterns in bladder cancer. Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2025.12.006 [0.03%]
Kiyo Yoshida,Souichi Oka,Yoshiyasu Takefuji
Kiyo Yoshida
Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel - A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials [0.03%]
Charles Vauchier,Constance Thibault,Maud Velev et al.
Charles Vauchier et al.
Background and objective: Optimal therapy after docetaxel and an androgen receptor pathway inhibitor (ARPI) in metastatic castration-resistant prostate cancer (mCRPC) remains debated. We aimed to build and validate the ca...
Deep Systemic Response in Muscle-invasive Bladder Cancer: Is Radical Cystectomy Still Necessary? [0.03%]
Xu-Shan Sun,Jihane Boustani,Roger Sun
Xu-Shan Sun
Re: Michael Baboudjian, Alessandro Uleri, Julien Anract, et al. Targeted, Perilesional, and Distant Biopsies in Prostate Cancer. Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.02.006 [0.03%]
Alexander Light,Hashim U Ahmed,Taimur T Shah
Alexander Light
Re: Sebastian C. Schmid, Matthias Jahnen, Kilian Schiller, et al. Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT). Eur Urol Oncol. In press. http://doi.org/10.1016/j.euo.2026.02.019 [0.03%]
Neeraj Singh,Monika Srivastav
Neeraj Singh
Design and Rationale of the ROGUE-1 Registry: A Multicentric Prospective Registry for Primary T1 Nonmuscle-invasive Bladder Cancer [0.03%]
David D&#x;Andrea,Francesco Soria,Morgan Rouprêt et al.
David D&#x;Andrea et al.
Background and objective: Patients with T1 nonmuscle-invasive bladder cancer (NMIBC) face substantial risks of recurrence and progression to muscle-invasive disease. However, current risk stratification tools rely on retr...
Re: Andrisha-Jade Inderjeeth, Andrew J Martin, Robert R Zielinski et al. Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304). Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.01.008 [0.03%]
无前列腺特异性抗原进展的转移性激素敏感性前列腺癌的放射学进展：ENZAMET试验（ANZUP 1304）的回顾性分析
Phuoc T Tran,Matthew P Deek,Philip Sutera
Phuoc T Tran
Extended Follow-up from the Stereotactic Body Radiotherapy for High-risk Localized Carcinoma of the Prostate (SHARP) Consortium: Updated Analysis of 440 Patients [0.03%]
大体积局灶性前列腺癌立体定向放疗(SHARP)联盟的长期随访结果：440例患者分析
Luca F Valle,Tahmineh Romero-Kalbasi,Tommy Jiang et al.
Luca F Valle et al.
Background and objective: Most patients with high-risk localized prostate cancer (HRLPC) do not undergo stereotactic body radiotherapy (SBRT) in part because of the limited evidence of long-term outcomes. We report long-t...
Integrating Genomic Prostate Score with Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores to Predict Biochemical Recurrence after Radical Prostatectomy [0.03%]
联合基因组前列腺评分与术前和术后前列腺癌风险评估评分预测根治性前列腺切除术后生化复发
Yu Ozawa,Marcio Covas Moschovas,Marco Sandri et al.
Yu Ozawa et al.
Background and objective: Cancer of the Prostate Risk Assessment (CAPRA) score and its postsurgical variant (CAPRA-S) predict biochemical recurrence (BCR) after radical prostatectomy (RP) but do not capture tumor biology....
Associations Between Quality of Life and Disease Progression in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials [0.03%]
PROSTATE ARASENS和ARANOTE研究中转移性激素敏感型前列腺癌患者生活质量与疾病进展的相关性分析
Alicia K Morgans,Sara Ekberg,Martin Boegemann et al.
Alicia K Morgans et al.
Background: Maintaining quality of life (QoL) is an important treatment goal in metastatic hormone-sensitive prostate cancer (mHSPC). Evidence remains limited regarding longitudinal QoL changes, prognostic value, and cont...